What Octapharma does

Octapharma AG is a privately-held, family-owned pharmaceutical company founded in 1983 and headquartered in Lachen, Switzerland. It is one of the largest human protein manufacturers in the world, developing and producing life-saving medicines derived from human plasma and human cell lines across three therapeutic areas: Haematology (haemophilia A and B, von Willebrand disease), Immunotherapy (primary and secondary immunodeficiencies, autoimmune disorders), and Critical Care (coagulopathy, major bleeding, hypovolemia). The company's portfolio comprises 14 core products including recombinant and plasma-derived factor concentrates (Nuwiq, octanate, octanine F, wilate), intravenous and subcutaneous immunoglobulins (octagam, panzyga, cutaquig, gammanorm), and critical care products (fibryga, octaplex, albunorm, atenativ, octaplasLG, rhesonativ).

Octapharma operates a vertically integrated supply chain anchored by 197+ company-owned plasma donation centres in the USA and Germany, which supply 88% of the 8 million liters of plasma collected annually. Plasma is processed at five state-of-the-art manufacturing sites in Stockholm, Vienna, Lingolsheim, Springe, and Dessau, using fractionation, purification, and the company's pioneering solvent/detergent (S/D) viral inactivation method combined with nanofiltration. Seven pre-clinical and clinical R&D sites across Germany, Switzerland, and elsewhere support a portfolio that generated €117M of R&D investment and €331M of capex in 2025, with total future-prosperity expenditures of €430M.

The company sells through dedicated Sales and Marketing teams and International Business Units, reaching patients in 115-120 countries across Europe, North America, Latin America, Asia Pacific, the Middle East, and Africa. Products are used to treat hundreds of thousands of patients annually. In 2025, Octapharma reported record revenue of €3.64 billion (+5% YoY), operating income of €577M (+8.5%), and net income of €453M. Recent strategic moves include the February 2026 USD 11.75M Series A lead investment in Abram Scientific (marking its first major move into diagnostics via the CoagCare platform), the 2024 FDA approval for Wilate, the 2023 exclusive plasma supplier appointment by NHS England, and the 2026 launch of the OctaplasLG lyophilized plasma formulation for pre-hospital critical care.

Name

Octapharma

Legal name

Octapharma AG

Website

https://octapharma.com

Company type

Private

Founded year

1983

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Octapharma is a family-owned Swiss biopharmaceutical company that develops and manufactures plasma-derived and recombinant therapies across haematology, immunotherapy, and critical care, serving patients in 115-120 countries through a vertically integrated network of 197+ plasma donation centres and five manufacturing sites.

Ownership category

akta.pro rank

Product category

Plasma-derived Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Plasma-Derived Therapeutics (immunoglobulins, albumin, clotting factors) (HLAAAAAI)

akta.pro secondary industries

Plasma Fractionation & Purification Manufacturing (HLAIAHAI), Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH), Plasma-Derived Protease Inhibitors & Complement Modulators (e.g., C1 Esterase Inhibitor) (HLAIAHAF), Plasma-Derived Therapy Quality, Safety & Pharmacovigilance (Pathogen Reduction/Testing) (HLAIAHAK), Plasma-Derived Therapy Fill-Finish & Packaging (HLAIAHAJ)

Keywords

• Plasma-derived therapeutics
• Human protein products
• Haematology treatments
• Immunoglobulin therapy
• Critical care medicines

Headquarters

HQ city

Lachen

HQ country

Switzerland

HQ region

Europe

Offices16 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Plasma-derived therapeutics sales: Octapharma develops and produces medicines based on proteins derived from human cell lines and human plasma. Products are sold globally across three therapeutic areas: haematology, immunotherapy, and critical care, treating hundreds of thousands of patients annually.
2. Pharmaceutical excipients: Octapharma supplies pharmaceutical-grade excipients for research and manufacturing needs to industrial customers worldwide, including human serum albumin, virus inactivated plasma, and human normal immunoglobulins.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

Octapharma develops and manufactures plasma-derived and recombinant protein therapies across three therapeutic areas: haematology (treatments for haemophilia A, haemophilia B, and von Willebrand disease), immunotherapy (intravenous and subcutaneous immunoglobulins for primary/secondary immunodeficiencies and autoimmune disorders), and critical care (fibrinogen concentrate, prothrombin complex concentrate, albumin, antithrombin, and pharmaceutically licensed plasma). The company sells these 14 core life-saving medicines to healthcare providers, hospitals, and government health systems across 115-120 countries.

Product overview

Octapharma develops and manufactures life-saving therapies derived from human plasma and human cell lines, organized across three therapeutic areas: Haematology, Immunotherapy, and Critical Care. The product portfolio consists of 14 core plasma-derived and recombinant products including: haemophilia treatments (Nuwiq®, octanate®, octanine®F, wilate®); immunoglobulin therapies administered intravenously and subcutaneously (octagam®, panzyga®, cutaquig®, gammanorm®); critical care products for bleeding management and haemostasis (fibryga®, octaplex®, albunorm®, atenativ®, octaplasLG®); and rhesonativ® for Rh disease prevention. The company operates company-owned plasma donation centres and manufactures at five state-of-the-art production sites to ensure supply security across 120 countries.

Differentiator

Problem solved

Functional benefit

Brands

• Albunorm: Human Albumin Solution for critical care
• Atenativ
• Cutaquig
• Fibryga
• Gammanorm
• Nuwiq
• Octagam
• Octanate
• Octanine F
• OctaplasLG
• Octaplex
• Panzyga
• Rhesonativ
• Wilate
• VWDtest.com
• Science Hub
• OneSource

Products and services

• albunorm® Human Albumin Solution used in critical care for restoring blood volume and maintaining hemodynamic stability in critically ill patients.
• atenativ® Human Antithrombin III Concentrate used for treating and preventing thromboembolism in patients with antithrombin deficiency.
• cutaquig® Subcutaneous Human Normal Immunoglobulin for immunotherapy, supporting the immune system in patients with primary and secondary immunodeficiencies.
• fibryga® Human Fibrinogen Concentrate for critical care, used to restore fibrinogen levels in patients with acquired fibrinogen deficiency during major bleeding.
• gammanorm® Subcutaneous Human Normal Immunoglobulin for immunotherapy, providing immune replacement therapy for patients with primary immunodeficiencies.
• Nuwiq® Human Coagulation Factor VIII (rDNA) (simoctocog alfa) for treating and preventing bleeding in patients with haemophilia A.
• octagam® Intravenous Human Normal Immunoglobulin for immunotherapy, used for immune replacement and immunomodulatory therapy in various immunodeficiency and autoimmune conditions.
• octanate® Human plasma-derived coagulation factor VIII concentrate, naturally stabilised with von Willebrand factor, for treating haemophilia A.
• octanine®F High-purity plasma-derived human factor IX concentrate for treating and preventing bleeding in patients with haemophilia B.
• octaplasLG® Pharmaceutically Licensed Plasma, a lyophilized plasma product designed for critical pre-hospital environments, providing multiple coagulation factors for bleeding management.
• octaplex® Human Prothrombin Complex Concentrate for critical care, used for rapid reversal of warfarin therapy and treatment of bleeding in patients with factor deficiency.
• panzyga® Intravenous Human Normal Immunoglobulin for immunotherapy, offering flexible dosing for immune replacement in primary immunodeficiencies and immunomodulation in autoimmune conditions.
• rhesonativ® Anti-D Immunoglobulin for preventing Rh isoimmunisation in Rh-negative women during pregnancy and after delivery of Rh-positive babies.
• wilate® High-purity, human von Willebrand factor/coagulation factor VIII complex concentrate for routine prophylaxis to reduce bleeding frequency in patients with von Willebrand disease.
• CoagCare Portable Coagulation Diagnostic Platform Next-generation portable coagulation diagnostic platform intended for use in trauma, surgery, and critical care that delivers results in under 10 minutes and provides a comprehensive coagulation profile in a portable format.
• Pharmaceutical Excipients (Industrial Collaboration) Pharmaceutical-grade excipients (human serum albumin, virus inactivated plasma, and human normal immunoglobulins) supplied to industrial pharmaceutical and research customers worldwide for use in research and manufacturing.

Quantifiable outcome

• Reduction in proportion of patients with severe infections by almost 50% for CLL patients with secondary immunodeficiency using intravenous human normal immunoglobulin
• +2 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Two partnerships are on record, tiered core and minor.

• NHS EnglandcoreOthers · 1 January 2023In 2023, Octapharma was selected to be the exclusive supplier of plasma to the National Health Service (NHS) in England after the government lifted a longstanding ban on the use of UK plasma. Octapharma was appointed sole fractionator for UK's plasma programme.
• GeBlod (Swedish National Blood Donation Service)minorOthersOctapharma Sweden collaborates with GeBlod, hosting mobile blood donation drives on GeBlod's 'blood bus' at its Stockholm production site. Octapharma allows employees to donate during working hours to support Sweden's blood supply.

Scale indicators20 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• CSL Behring: CSL Behring is the global leader in plasma-derived therapeutics (immunoglobulins, albumin, clotting factors) and operates the world's largest private plasma collection network. It is Octapharma's most direct head-to-head competitor across all three therapeutic areas.
• Grifols: Grifols is a vertically integrated Spanish plasma therapeutics manufacturer with plasma collection, fractionation and a broad immunoglobulin/albumin portfolio. Competes directly with Octapharma on supply security, IVIG/SCIG, and specialty coagulation products.
• Kedrion Biopharma: Kedrion is an Italy-based plasma fractionator with a portfolio of immunoglobulins, clotting factors and albumin and a growing plasma collection network. It is one of the closest mid-sized comparables to Octapharma in business model and therapeutic scope.
• Bio Products Laboratory (BPL): BPL is a UK-based plasma fractionator producing immunoglobulins, albumin and coagulation products, and operates the UK's fractionation infrastructure. It competes with Octapharma in European markets and on national plasma supply contracts.
• Biotest AG: Biotest is a German plasma-derived therapeutics specialist focused on immunoglobulins, clotting factors and albumin, with its own plasma collection. Recently acquired by Grifols, it remained a direct peer in product mix and European footprint prior to the takeover.

Broad incumbents

• Takeda Pharmaceutical (Shire): Takeda acquired Shire's plasma-derived therapeutics franchise (now Takeda Manufacturing Italia) and competes with Octapharma in immunoglobulins and albumin. As a diversified global pharma major, it has broader capital and pipeline resources than Octapharma.
• Sanofi (Plasma/Immunoglobulin franchise): Sanofi is a global biopharmaceutical major with a specialty care immunoglobulin portfolio (e.g., HyQvia, Hizentra via collaborations). As a broad incumbent, it overlaps with Octapharma in immunotherapy while having far larger total scale and capital access.
• Pfizer (haemophilia franchise): Pfizer markets recombinant coagulation factors (e.g., BeneFIX, Xyntha/ReFacto) and competes with Octapharma's haemophilia portfolio. As a diversified pharma incumbent, it competes on recombinant factor share rather than plasma-derived depth.

Emerging players

• Bio-Rad Laboratories: Bio-Rad provides diagnostic and quality-control systems used alongside plasma therapeutics manufacturing and hospital blood testing. It is adjacent to Octapharma's diagnostics push via Abram Scientific / CoagCare in the coagulation diagnostics space.

Others

• Roche (Diagnostics): Roche operates one of the largest in vitro diagnostics businesses globally, including coagulation testing. It is an indirect competitor and ecosystem participant as Octapharma expands into diagnostics-adjacent offerings around its Critical Care franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCYgtXBu91QV8lGB1P6vIbCA
• LinkedInlinkedin.com/company/octapharma
• Xx.com/octamenairan
• Facebookfacebook.com/185003471553021

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries20 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Octapharma